Table 2 Univariate analysis (log-rank test/Cox regression), influence on post-recurrence survival (PRS) and post-recurrence progression-free survival (PR-PFS)

Age (< 50 y, ≥ 50 y)

ns (p = 0.717)/ns (p = 0.854)

KPS (< 70, ≥ 70)

ns (p = 0.156)/ns (p = 0.095)

MGMT (meth/not meth)

ns (p = 0.897)/ns (p = 0.711)

Initial WHO grade (II/III/IV)

ns (p = 0.996)/ns (p = 0.922)

Bevacizumab (no/yes)

p = 0.027/ns (p = 0.396)

Adjuvant/Salvage chemotherapy (no/yes)

ns (p = 0.108)/ns (p = 0.054)

Sex (male/female)

ns (p = 0.410)/ns (p = 0.304)

Time interval (≤ 12 y, > 12 y)

ns (p = 0.672)/ns (p = 0.349)